Salix presents data to expand markets for bowel disorder drugs Xifaxan and Relistor
This article was originally published in Scrip
After a subset analysis of two previously reported Phase III studies with positive results for Xifaxan (rifaximin) in the treatment of non-constipation irritable bowel syndrome, Salix Pharmaceuticals shared data at a conference in San Diego on 22 May showing no major differences in efficacy for men and women with IBS who were treated with the minimally absorbed antibiotic.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.